Societies, associations and institutes also develop clinical guidelines for the treatment and management of psoriasis at local, national, and international levels.
EADV Guidelines - Europe
The S3-guidelines for the treatment of psoriasis provide an overview of a variety of practical aspects relevant to selecting drugs and monitoring patients on therapy.
Based on the evaluation of efficacy and safety data, as well as on the practical experience obtained with different treatment modalities, they contain a range of recommendations reached in a structured consensus process.
Joint AAD-NPF topical treatment guidelines
Guidelines for the management of psoriasis with topical therapies were developed by the American Academy of Dermatology (AAD) in 2009 (Menter et al., 2009). These guidelines highlight that the majority of patients with psoriasis have limited disease (<5% body surface area [BSA] involvement) and can be safely and effectively treated with topical agents tailored to meet individual patients’ needs (Menter et al., 2009). Updates to these guidelines are expected to be published by the AAD in collaboration with the National Psoriasis Foundation (NPF) in the second quarter of 2020.
The International Psoriasis Council
Psoriasis is such an active field of research and the pace at which new treatments are becoming approved makes it difficult for the guidelines to keep up. In addition, with the vastly improved treatment armamentarium it has been recognised that improving the classification of psoriasis severity would be of benefit for treatment decision-making.
The International Psoriasis Council (IPC), founded in 2004, is a dermatology-led, global, non-profit organisation with a network of more than 100 psoriasis experts, thought leaders, and professionals, dedicated to improving patient care around the globe. Their aim is to deepen the understanding of the disease and its management and believe that ultimately a world without psoriasis is possible. The IPC recognises that the current clinical definitions of psoriasis severity are narrowly defined and overlook the unique challenges faced by each patient, which may include localised lesions in specific areas and/or comorbidities. A consensus is needed to define each category of disease severity in order to improve the care of all patients with psoriasis worldwide.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Almirall S.A, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.